Arbaclofen - AGI Therapeutics

Drug Profile

Arbaclofen - AGI Therapeutics

Alternative Names: AGI-006; R-baclofen - AGI Therapeutics

Latest Information Update: 15 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AGI Therapeutics
  • Class Aminobutyric acids; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux; Gastroparesis; Nausea and vomiting
  • Discontinued Non-ulcer dyspepsia

Most Recent Events

  • 15 May 2014 No development reported - Preclinical for Gastro-oesophageal reflux in Europe (PO)
  • 15 May 2014 No development reported - Preclinical for Gastroparesis in Europe (PO)
  • 15 May 2014 No development reported - Preclinical for Nausea and vomiting in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top